Cure My Disease

Don't miss your cure!

 Log in / Sign up

New tests aim to take the guesswork out of lung cancer immunotherapy

NCT ID NCT06405230

Recruiting now Knowledge-focused Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Feb 03, 2026 · Last updated May 15, 2026 · Updated 11 times

Summary

This study looks at new ways to predict if immunotherapy drugs (dostarlimab and pembrolizumab) will work for people with advanced lung cancer that has come back. Researchers will use blood tests, lab-grown tumor models, and special PET scans to see if these tools can forecast treatment response. About 40 participants will join this early-phase study to help improve personalized cancer care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER (NON-SMALL CELL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • GSK Investigational Site

    RECRUITING

    London, SE1 9RT, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

LUNG CANCER (NON-SMALL CELL)